Idiopathic Pulmonary Fibrosis (IPF)

Wood dust, one exposure linked to IPF
Wood dust, one exposure linked to IPF

Idiopathic pulmonary fibrosis is a chronic, progressive, irreversible scarring lung disease of unknown cause that destroys the lung architecture through an abnormal wound-healing response; it is the most common and most lethal of the idiopathic interstitial pneumonias, with a median survival of 3–5 years from diagnosis. Two long-established antifibrotic drugs — nintedanib and pirfenidone — slow progression but do not reverse established fibrosis, and a third, nerandomilast, was approved in the United States in 2025.

Table of Contents

  1. What Causes IPF: Pathogenesis
  2. The UIP Pattern: Histology and Imaging
  3. Diagnosis: When Biopsy Is Needed
  4. Monitoring Lung Function Decline
  5. Nintedanib: Antifibrotic Therapy
  6. Pirfenidone: The First Antifibrotic
  7. Nerandomilast: The Third Approved Antifibrotic
  8. Lung Transplantation
  9. Symptom Management and Palliative Care
  10. Key Research Papers
  11. Featured Videos

What Causes IPF: Pathogenesis

The defining cellular event in IPF is repetitive micro-injuries to the alveolar epithelium — the thin cells lining the tiny air sacs — that trigger an aberrant, self-perpetuating wound-healing response rather than normal tissue repair. In normal wound healing, fibroblasts briefly proliferate to repair a defect, then apoptosis removes them; in IPF, fibroblasts transform into myofibroblasts that resist apoptosis and continue depositing collagen and extracellular matrix indefinitely. The result is progressive replacement of functional lung tissue with dense, stiff scar tissue.

Known and suspected triggers for alveolar injury include cigarette smoke (strong association, 75% of IPF patients are current or former smokers), gastroesophageal reflux with micro-aspiration of acid into the lungs, environmental exposures (metal dusts, wood dust — particularly pine — textile fibers), viral infections (Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpesvirus group), and aging itself (median age at diagnosis: 66 years; very rare under 50). The lung's regenerative capacity declines with age, and senescent type II alveolar epithelial cells in IPF patients secrete a senescence-associated secretory phenotype (SASP) that promotes fibroblast activation.

Genetic factors are important: familial IPF (10% of cases) involves mutations in genes encoding surfactant proteins (SFTPC, SFTPA2), telomerase (TERT, TERC — accounting for ~25% of familial IPF), and TOLLIP (innate immune signaling). A common variant in the MUC5B gene promoter (rs35705950) is the strongest genetic risk factor for sporadic IPF. In the 2011 study that found it (Seibold et al.), the variant made up about 38% of the gene copies in people with IPF versus 9% in people without it; one copy raised the odds of IPF about 9-fold and two copies about 22-fold (odds ratios 9.0 and 21.8) — though paradoxically this same variant is associated with better prognosis once IPF is established.

Back to Table of Contents

The UIP Pattern: Histology and Imaging

The pathological hallmark of IPF is the Usual Interstitial Pneumonia (UIP) pattern — a specific spatial distribution of fibrosis characterized by three features: (1) temporal heterogeneity (areas of dense old fibrosis beside areas of active "fibroblastic foci" where new collagen is being deposited — old and new disease coexisting in the same biopsy); (2) spatial heterogeneity (normal lung alternating with fibrotic lung in a patchwork pattern); and (3) predominantly subpleural and basal distribution (fibrosis maximal at the lung bases and just under the pleural surface, with relative sparing of upper lobes).

On High-Resolution CT (HRCT), UIP appears as: honeycombing (clustered cystic airspaces, typically subpleural, 3–10 mm diameter — the most specific finding); traction bronchiectasis and bronchiolectasis (airways pulled open and distorted by surrounding fibrosis); subpleural, basal-predominant reticulation (a fine mesh-like pattern of thickened interstitium); and minimal or absent ground glass opacity (if prominent ground glass opacity is present, it suggests an alternative diagnosis such as NSIP or HP). The 2022 ATS/ERS/JRS/ALAT guidelines define computed tomography (CT) patterns as: Typical UIP (diagnostic of IPF if clinical context fits, surgical biopsy not needed), Probable UIP, Indeterminate, and Alternative Diagnosis (suggests a different ILD).

Distinguishing UIP from other ILD patterns matters enormously because prognosis and treatment differ: Non-specific interstitial pneumonia (NSIP) — the second most common IIP — has lower mortality and responds to immunosuppression; Hypersensitivity Pneumonitis (HP) may halt progression if the causative antigen is removed; Organizing Pneumonia responds to corticosteroids. A meticulous clinical history covering occupational exposures, bird ownership, hot tubs, and rheumatological symptoms is essential before accepting an IPF diagnosis.

Back to Table of Contents

Diagnosis: When Biopsy Is Needed

IPF is a diagnosis of exclusion: all known causes of UIP-pattern fibrosis are ruled out before the idiopathic label is assigned. The diagnostic workup is systematic and multidisciplinary.

Clinical History and Serology

A detailed occupational and environmental exposure history is the first step — asking about bird or feather exposure, hot tubs, metal and wood dusts, and textile work. Systemic symptoms of connective tissue disease are looked for: joint swelling, dry eyes or dry mouth, skin thickening, Raynaud's phenomenon all suggest CTD-ILD, which is managed differently from IPF. Connective tissue disease serology includes antinuclear antibody (ANA), rheumatoid factor, anti-CCP, SSA/SSB (Sjögren's), Scl-70 and anti-centromere (scleroderma), and a myositis antibody panel (Jo-1, MDA5). CTD-ILD requires treatment of the underlying autoimmune condition, not just antifibrotics.

HRCT and BAL

HRCT chest is the cornerstone of diagnosis. A typical UIP pattern on HRCT by an experienced radiologist in a patient over 60 with no identifiable cause is sufficient for IPF diagnosis under the 2022 guidelines — surgical lung biopsy is not required. This represents a significant liberalization from older guidelines that required biopsy more often. Bronchoalveolar lavage (BAL) is used primarily to exclude alternative diagnoses: lymphocytosis above 30% suggests HP or NSIP; eosinophilia above 25% suggests eosinophilic pneumonia; hemosiderin-laden macrophages suggest diffuse alveolar hemorrhage. In classic IPF, BAL shows neutrophilia without striking lymphocytosis.

Surgical Lung Biopsy and Multidisciplinary Discussion

Surgical lung biopsy by video-assisted thoracoscopic surgery (VATS) is required only when HRCT is not diagnostic — a probable or indeterminate pattern. VATS biopsy samples are taken from at least two lobes to capture the spatial heterogeneity of UIP. Cryobiopsy — a bronchoscopic frozen-tissue biopsy — is no longer only an emerging option: the 2022 guideline made a conditional recommendation to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise, which matters most for patients who are poor surgical candidates. The 2022 guidelines place strong emphasis on multidisciplinary discussion (MDD): diagnosis by a team of pulmonologist, radiologist, and pathologist with ILD expertise, rather than by any single specialist alone. Diagnosis at non-specialist centers carries a 30–50% diagnostic error rate.

Back to Table of Contents

Monitoring Lung Function Decline

IPF causes a restrictive ventilatory defect: FVC (Forced Vital Capacity) and TLC (Total Lung Capacity) are reduced; FEV1/FVC ratio is preserved or elevated; and DLCO (Diffusing Capacity for Carbon Monoxide) is disproportionately reduced, reflecting destruction of alveolar surface area where gas exchange occurs. DLCO decline often precedes FVC decline and is the more sensitive early marker of gas-exchange impairment.

The 6-Minute Walk Test (6MWT) assesses functional capacity and captures oxygen desaturation that may not occur at rest. Desaturation during walking (SpO2 fall to below 88–90%) occurs frequently in IPF and is associated with poor prognosis. Exercise-induced hypoxemia is common even when resting oxygen saturation is normal, making the 6MWT an essential component of every clinic visit. Monitoring frequency is PFTs and 6MWT every 3–6 months, and HRCT annually or when clinically indicated.

FVC decline of 10% or more in 6–12 months is a robust prognostic marker: patients with this degree of decline have 2–3 times higher mortality than those with stable FVC. This threshold is used as both a clinical trial endpoint and a trigger for escalation of care, including expedited transplant listing. A decline of 5–10% is considered clinically meaningful even if it does not cross the 10% threshold.

Acute exacerbation of IPF (AE-IPF) is a catastrophic, life-threatening event defined as acute worsening with new bilateral ground glass opacities on computed tomography not explained by heart failure, fluid overload, or infection. AE-IPF occurs in 5–15% of patients per year, carries 50–80% hospital mortality, and accelerates progression in survivors. Triggers include respiratory infections, surgical procedures, and aspiration; most episodes are idiopathic. No proven treatment exists; high-dose corticosteroids are commonly used despite very limited supporting evidence.

Back to Table of Contents

Nintedanib: Antifibrotic Therapy

Nintedanib is an oral tyrosine kinase inhibitor that targets the growth factor receptors PDGFR (platelet-derived growth factor receptor), VEGFR (vascular endothelial growth factor receptor), and FGFR (fibroblast growth factor receptor). These receptors are overactivated in IPF and drive fibroblast proliferation, migration, and collagen deposition. By blocking all three receptor families simultaneously, nintedanib interrupts multiple pro-fibrotic signaling pathways at once — a triple-receptor strategy designed to overcome the redundancy of fibrotic signaling.

The INPULSIS trials (Richeldi et al., NEJM 2014) — two identical parallel Phase 3 randomized controlled trials (RCTs) enrolling 1,066 patients — demonstrated that nintedanib 150 mg twice daily slowed the annual rate of FVC decline: −114.7 mL/year with nintedanib versus −239.9 mL/year with placebo in INPULSIS-1, and −113.6 mL/year versus −207.3 mL/year in INPULSIS-2 — roughly half the loss of lung function. Time to first acute exacerbation was significantly longer in the nintedanib group in one of the two trials (INPULSIS-2). Overall survival did not differ significantly in the 52-week trial period, though pooled analyses suggest a survival signal.

Side effects are primarily gastrointestinal: diarrhea occurs in approximately 60% of patients (61.5% and 63.2% in the two INPULSIS trials, versus about 18% on placebo) (manageable in most with antidiarrheal agents, hydration, and dose reduction to 100 mg twice daily if needed); nausea affects ~25% and vomiting ~10%; liver enzyme elevation (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)) requires monthly monitoring for the first 3 months then quarterly thereafter. Nintedanib is teratogenic; effective contraception is mandatory in women of childbearing potential. The drug label lists two main interaction concerns: nintedanib may increase the risk of bleeding, so the label calls for close monitoring for bleeding in patients on full anticoagulation therapy; and drugs that block P-glycoprotein and the CYP3A4 enzyme raise nintedanib levels — ketoconazole increased nintedanib exposure by 60%. Nintedanib has expanded approvals: it is now also approved for progressive fibrotic ILD of any cause (not just IPF) and for ILD associated with systemic sclerosis (SSc-ILD), based on the SENSCIS trial.

Back to Table of Contents

Pirfenidone: The First Antifibrotic

Pirfenidone is an oral small molecule that was the first antifibrotic drug approved for IPF, receiving approval in Japan in 2008, the European Union in 2011, and the United States in 2014. Its mechanism is less precisely defined than nintedanib: pirfenidone inhibits TGF-β (transforming growth factor beta — the master pro-fibrotic cytokine), reduces fibroblast proliferation, and has anti-inflammatory and antioxidant properties in vitro, though its exact primary molecular target has not been fully elucidated.

The ASCEND trial (King et al., NEJM 2014), the two earlier CAPACITY trials (studies 004 and 006, run in 110 centres in Australia, Europe and North America), and a Japanese phase 3 trial (Taniguchi et al., 2010) established the evidence base. In CAPACITY, study 004 showed less FVC decline with pirfenidone at 72 weeks, while study 006 did not reach its main lung-function goal at 72 weeks (p=0.501). ASCEND enrolled 555 patients and showed that, over 52 weeks, pirfenidone cut the proportion of patients whose predicted FVC fell by 10 percentage points or more, or who died, by 47.9% relative to placebo. A prespecified pooled analysis of ASCEND and the two CAPACITY trials found significantly fewer deaths from any cause with pirfenidone. The standard dose is pirfenidone 801 mg three times daily (2,403 mg/day total), titrated up over several weeks to improve tolerability.

Side effects include photosensitivity — sunburn reactions even with brief sun exposure (9% on pirfenidone versus 1% on placebo in the phase 3 studies, mostly in the first 6 months); the drug label calls for avoiding or minimizing sunlight, a sunblock of SPF 50 or higher, and sun-protective clothing; rash; nausea and anorexia (minimized by taking pirfenidone with food, dividing doses across three main meals); dizziness; and fatigue. Liver function monitoring is recommended. Critically, CYP1A2 inducers such as cigarette smoke and rifampicin significantly reduce pirfenidone blood levels, while CYP1A2 inhibitors such as fluvoxamine markedly increase them. This makes smoking cessation doubly important in IPF: tobacco smoke is a disease trigger and a drug interaction that undermines treatment efficacy.

No direct head-to-head trial between nintedanib and pirfenidone exists. Both reduce the annual rate of FVC decline by approximately 50% compared to placebo. Choice between them is guided by side effect profile preference, insurance coverage, patient lifestyle (sun exposure), and comorbidities — nintedanib is preferred when gastrointestinal (GI) side effects are manageable; pirfenidone may be preferred when diarrhea would be particularly burdensome. Some patients who cannot tolerate one agent are switched to the other.

Back to Table of Contents

Nerandomilast: The Third Approved Antifibrotic

Nerandomilast is a tablet that works differently from the two older drugs: it mainly blocks one form of the enzyme phosphodiesterase 4 (phosphodiesterase 4B), which has antifibrotic and immune-calming effects. It was approved in the United States in 2025.

In the FIBRONEER-IPF trial (Richeldi et al., NEJM 2025), 1,177 patients with IPF were randomly assigned to nerandomilast 18 mg twice daily, 9 mg twice daily, or placebo; 77.7% were already taking nintedanib or pirfenidone. After 52 weeks, lung capacity (FVC) had fallen by 114.7 mL on 18 mg and 138.6 mL on 9 mg, compared with 183.5 mL on placebo. Diarrhea was the most common side effect: 41.3% on 18 mg and 31.1% on 9 mg, against 16.0% on placebo. Serious side effects were balanced across the groups.

A 2026 analysis that pooled FIBRONEER-IPF with the companion FIBRONEER-ILD trial (people with progressive pulmonary fibrosis) looked at deaths. Over an average of 16.7 months, the risk of death compared with placebo was 43% lower with 18 mg twice daily (hazard ratio 0.57) and 33% lower with 9 mg twice daily (hazard ratio 0.67). Time to death was a secondary result in the trials, and the trials' key secondary endpoint was not met; the authors' further checks found the survival result consistent.

Back to Table of Contents

Lung Transplantation

Lung transplantation is the only treatment with the potential for extended long-term survival in IPF, and IPF is the most common indication for lung transplantation worldwide, representing approximately 30% of all lung transplants performed annually. Bilateral lung transplantation (BLT) is strongly preferred over single lung transplant (SLT) for IPF: BLT provides significantly longer median survival (5 or more years for BLT vs. 3–4 years for SLT), because in SLT the remaining native lung — with its markedly reduced compliance from fibrosis — creates ventilation-perfusion mismatch that compromises the transplanted lung over time.

Referral criteria from the ATS/ERS guidelines call for referring IPF patients to a transplant center at the time of diagnosis, not waiting for severe decline. Listing criteria include FVC below 80% predicted, DLCO below 40%, FVC decline of 10% or more in 6 months, SpO2 below 88% during 6MWT, honeycombing on computed tomography with a fibrosis score above 2, and pulmonary hypertension on echocardiogram or right heart catheterization. Mean time on the lung transplant waitlist for IPF exceeds one year in the United States; patients die on the waitlist at high rates if listed too late, making early referral a life-or-death decision.

Post-transplant 5-year survival for IPF is approximately 50–55%, comparable to the overall lung transplant population average of 57%. Primary graft dysfunction (PGD) — severe reperfusion injury in the first 72 hours — is more common after IPF transplant than other indications. Chronic lung allograft dysfunction (CLAD) — most commonly manifesting as bronchiolitis obliterans syndrome (BOS) — is the leading cause of death beyond one year post-transplant. Patients require lifelong immunosuppression with tacrolimus, mycophenolate mofetil, and low-dose prednisone. Antifibrotic drugs are generally discontinued after successful transplantation.

Back to Table of Contents

Symptom Management and Palliative Care

The progressive dyspnea of IPF imposes a severe burden on patients and caregivers. Symptom management is a critical component of care that, in current practice, begins alongside antifibrotic therapy rather than being reserved for the terminal phase. IPF shares the dismal prognosis of many cancers but patients are far less often offered palliative care consultation at an early stage.

Oxygen and Pulmonary Rehabilitation

Supplemental oxygen is prescribed when resting SpO2 falls to 88% or below (the Medicare threshold in the US) or when desaturation on exertion is symptomatic. Ambulatory oxygen allows patients to maintain physical activity and reduces dyspnea during movement. Home oxygen does not slow IPF progression but significantly improves exercise tolerance and quality of life. Flow rates are set separately for rest and exertion — the exertion requirement is often two to three times higher than the resting requirement. Pulmonary rehabilitation — structured exercise training, education, and psychosocial support — improves 6MWT distance, dyspnea scores, and quality of life in IPF across multiple randomized controlled trials. Benefits tend to diminish as the disease progresses, but repeated rehabilitation referrals are reasonable.

Managing Cough, Reflux, and Dyspnea

Persistent dry cough occurs in most IPF patients and is severely disabling, yet no treatment has robust evidence in IPF specifically. The newest data come from the 2024 PACIFY COUGH crossover trial in 44 patients: low-dose slow-release morphine 5 mg twice daily for 14 days cut awake cough frequency by 39.4% compared with placebo (daytime coughs fell from 21.6 to 12.8 per hour on morphine, while placebo left them unchanged); nausea affected 14% and constipation 21% on morphine, and the authors call for longer studies. Thalidomide showed benefit in a small randomized controlled trial (RCT); low-dose prednisone provides temporary relief; gabapentin is used off-label. Emerging agents targeting P2X3 receptors such as gefapixant are in clinical trials. For gastroesophageal reflux, proton pump inhibitor (PPI) therapy is widely used in IPF; micro-aspiration is a putative trigger for alveolar micro-injury and acute exacerbations, and a large observational study suggested an association between proton pump inhibitor use and slower IPF progression, though no definitive randomized controlled trial exists. The 2022 ATS/ERS/JRS/ALAT guideline, after a systematic review, made conditional recommendations against antacid medication and antireflux surgery for the treatment of IPF itself. For refractory dyspnea in advanced IPF, oral low-dose opioids (oral morphine 5–10 mg every 4 hours as needed, or slow-release preparations) are effective palliation. The evidence base for opioids in dyspnea is strong across chronic lung conditions. Patient education matters here: opioids given at appropriate doses for dyspnea do not shorten life, a distinction from palliative sedation that frightens many patients and families.

Advance Care Planning

In palliative-care practice, goals-of-care conversations begin at the time of diagnosis rather than at the point of decompensation. They cover the disease trajectory, the limitations of antifibrotic therapy, and the likely path toward respiratory failure. Early integration of palliative care improves quality of life, reduces hospitalizations, and supports informed decision-making about mechanical ventilation (which does not improve survival in AE-IPF and is generally not recommended), hospice, and end-of-life preferences. IPF carries a prognosis comparable to many cancers, yet the proactive palliative care framework routinely offered to cancer patients is offered to IPF patients far less often.

Back to Table of Contents

Key Research Papers

  1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. — PubMed PMID: 35486072
  2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. — PubMed PMID: 24836310
  3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092. — PubMed PMID: 24836312
  4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. — PubMed PMID: 21471066
  5. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378(19):1811-1823. — PubMed PMID: 29742380
  6. Maher TM, Wuyts W. Management of Fibrosing Interstitial Lung Diseases. Adv Ther. 2019;36(7):1518-1531. — PubMed PMID: 31119691
  7. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821-829. — PubMed PMID: 19996196
  8. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 — An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15. — PubMed PMID: 25085497
  9. Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-275. — PubMed PMID: 27299520
  10. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013;68(5):436-441. — PubMed PMID: 23321605
  11. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309-317. — PubMed PMID: 24429156
  12. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60(7):588-594. — PubMed PMID: 15994268
  13. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769. — PubMed PMID: 21571362
  14. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503-1512. — PubMed PMID: 21506741
  15. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193-2202. — PubMed PMID: 40387033
  16. Oldham JM, Assassi S, Azuma A, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. Eur Respir J. 2026 (online ahead of print). — PubMed PMID: 42532543
  17. Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024;12(4):273-280. — PubMed PMID: 38237620
  18. US National Library of Medicine, DailyMed. Nintedanib capsules prescribing information, section 7 Drug Interactions. — DailyMed
  19. US National Library of Medicine, DailyMed. Pirfenidone tablets prescribing information, section 5.2 Photosensitivity Reaction or Rash. — DailyMed

PubMed Topic Searches

  1. IPF Pathogenesis — PubMed
  2. UIP Pattern on HRCT — PubMed
  3. IPF Diagnosis Guidelines — PubMed
  4. Nintedanib INPULSIS Trials — PubMed
  5. Pirfenidone ASCEND Trial — PubMed
  6. Lung Transplant for IPF — PubMed
  7. Acute Exacerbation of IPF — PubMed
  8. MUC5B Genetic Risk Factor — PubMed
  9. IPF Palliative Care & QoL — PubMed
  10. Pulmonary Rehabilitation in IPF — PubMed

Back to Table of Contents

Connections

Back to Table of Contents